"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","treatment_protocol_ch1","growth_protocol_ch1","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","data_processing","platform_id","contact_name","contact_email","contact_phone","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","disease state:ch1"
"GSM3359735","AD-2 chronic hepatitis C","GSM3359735","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359735/suppl/GSM3359735_SH68J29_Cell1_20161221_1543_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359736","AD-3 chronic hepatitis C","GSM3359736","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359736/suppl/GSM3359736_SH68J29_Cell2_20161221_1544_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359737","AD-5 chronic hepatitis C","GSM3359737","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359737/suppl/GSM3359737_SH68J29_Cell3_20161221_1545_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359738","AD-6 chronic hepatitis C","GSM3359738","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359738/suppl/GSM3359738_SH68J29_Cell4_20161221_1546_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359739","AD-11 chronic hepatitis C","GSM3359739","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359739/suppl/GSM3359739_SH68J30_Cell2_20161221_1548_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359740","AD-12 chronic hepatitis C","GSM3359740","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359740/suppl/GSM3359740_SH68J30_Cell3_20161221_1549_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359741","AD-27 chronic hepatitis C","GSM3359741","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359741/suppl/GSM3359741_SH68J30_Cell4_20161221_1550_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359742","AD-33 chronic hepatitis C","GSM3359742","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359742/suppl/GSM3359742_SH68J31_Cell1_20161221_1551_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359743","AD-36 chronic hepatitis C","GSM3359743","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359743/suppl/GSM3359743_SH68J31_Cell2_20161221_1552_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359744","AD-38 chronic hepatitis C","GSM3359744","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359744/suppl/GSM3359744_SH68J31_Cell3_20161221_1553_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359745","AD-39 chronic hepatitis C","GSM3359745","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359745/suppl/GSM3359745_SH68J31_Cell4_20161221_1554_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359746","AD-51 chronic hepatitis C","GSM3359746","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359746/suppl/GSM3359746_SH68J32_Cell1_20161221_1555_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359747","AD-52 chronic hepatitis C","GSM3359747","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359747/suppl/GSM3359747_SH68J32_Cell2_20161221_1556_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359748","AD-56 chronic hepatitis C","GSM3359748","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359748/suppl/GSM3359748_SH68J32_Cell3_20161221_1557_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359749","AD-58 chronic hepatitis C","GSM3359749","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359749/suppl/GSM3359749_SH68J32_Cell4_20161221_1558_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359750","AD-70 chronic hepatitis C","GSM3359750","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359750/suppl/GSM3359750_SH68J33_Cell1_20161221_1559_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359751","AD-82 chronic hepatitis C","GSM3359751","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359751/suppl/GSM3359751_SH68J33_Cell2_20161221_1600_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359752","AD-84 chronic hepatitis C","GSM3359752","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359752/suppl/GSM3359752_SH68J33_Cell3_20161221_1601_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359753","AD-94 chronic hepatitis C","GSM3359753","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359753/suppl/GSM3359753_SH68J33_Cell4_20161221_1602_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359754","AD-96 chronic hepatitis C","GSM3359754","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359754/suppl/GSM3359754_SH68J34_Cell1_20161221_1603_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359755","AD-97 chronic hepatitis C","GSM3359755","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359755/suppl/GSM3359755_SH68J34_Cell2_20161221_1604_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359756","AD-104 chronic hepatitis C","GSM3359756","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359756/suppl/GSM3359756_SH68J34_Cell3_20161221_1605_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359757","AD-105 chronic hepatitis C","GSM3359757","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359757/suppl/GSM3359757_SH68J34_Cell4_20161221_1633_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359758","AD-113 chronic hepatitis C","GSM3359758","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359758/suppl/GSM3359758_SH68J35_Cell1_20161221_1607_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359759","AD-122 chronic hepatitis C","GSM3359759","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359759/suppl/GSM3359759_SH68J35_Cell3_20161221_1609_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359760","AD-123 chronic hepatitis C","GSM3359760","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359760/suppl/GSM3359760_SH68J35_Cell4_20161221_1610_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359761","AD-129 chronic hepatitis C","GSM3359761","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359761/suppl/GSM3359761_SH68Y37_Cell1_20161221_1611_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359762","AD-131 chronic hepatitis C","GSM3359762","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359762/suppl/GSM3359762_SH68Y37_Cell2_20161221_1612_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359763","AD-132 chronic hepatitis C","GSM3359763","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359763/suppl/GSM3359763_SH68Y37_Cell3_20161221_1613_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359764","AD-137 chronic hepatitis C","GSM3359764","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359764/suppl/GSM3359764_SH68Y37_Cell4_20161221_1614_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359765","AD-142 chronic hepatitis C","GSM3359765","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359765/suppl/GSM3359765_SH68Y39_Cell1_20161221_1615_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359766","AD-154 chronic hepatitis C","GSM3359766","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359766/suppl/GSM3359766_SH68Y39_Cell2_20161221_1616_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359767","SL-27 chronic hepatitis C","GSM3359767","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359767/suppl/GSM3359767_SH68Y39_Cell3_20161221_1617_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359768","SL-49 chronic hepatitis C","GSM3359768","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359768/suppl/GSM3359768_SH68Y39_Cell4_20161221_1618_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359769","SL-65 chronic hepatitis C","GSM3359769","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359769/suppl/GSM3359769_SH68Y41_Cell1_20161221_1619_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359770","SL-99 chronic hepatitis C","GSM3359770","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359770/suppl/GSM3359770_SH68Y41_Cell2_20161221_1620_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359771","SL-108 chronic hepatitis C","GSM3359771","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359771/suppl/GSM3359771_SH68Y41_Cell3_20161221_1621_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359772","SL-162 chronic hepatitis C","GSM3359772","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359772/suppl/GSM3359772_SH68Y41_Cell4_20161221_1622_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359773","SL-208 chronic hepatitis C","GSM3359773","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359773/suppl/GSM3359773_SH68Y42_Cell1_20161222_1457_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359774","SL-220 chronic hepatitis C","GSM3359774","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359774/suppl/GSM3359774_SH68Y42_Cell2_20161222_1458_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359775","SL-226 chronic hepatitis C","GSM3359775","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359775/suppl/GSM3359775_SH68Y42_Cell3_20161222_1459_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359776","SL-268 chronic hepatitis C","GSM3359776","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359776/suppl/GSM3359776_SH68Y42_Cell4_20161222_1500_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359777","SL-284 chronic hepatitis C","GSM3359777","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359777/suppl/GSM3359777_SH68Y43_Cell1_20161222_1501_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359778","SR-8 chronic hepatitis C","GSM3359778","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359778/suppl/GSM3359778_SH68Y43_Cell2_20161222_1502_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359779","SR-59 chronic hepatitis C","GSM3359779","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359779/suppl/GSM3359779_SH68Y43_Cell3_20161222_1503_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359780","SR-81 chronic hepatitis C","GSM3359780","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359780/suppl/GSM3359780_SH68Y43_Cell4_20161222_1504_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359781","SL-157 chronic hepatitis C","GSM3359781","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359781/suppl/GSM3359781_SH74L44_Cell3_20170627_2013_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359782","SL-155 chronic hepatitis C","GSM3359782","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359782/suppl/GSM3359782_SH74L44_Cell4_20170627_2014_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359783","SL-154 chronic hepatitis C","GSM3359783","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359783/suppl/GSM3359783_SH74L45_Cell2_20170627_2016_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359784","SL-163 chronic hepatitis C","GSM3359784","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359784/suppl/GSM3359784_SH74L45_Cell3_20170627_2017_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359785","SL-166 chronic hepatitis C","GSM3359785","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359785/suppl/GSM3359785_SH74L45_Cell4_20170627_2018_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359786","SL-159 chronic hepatitis C","GSM3359786","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359786/suppl/GSM3359786_SH74L49_Cell1_20170627_2019_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359787","SL-160 chronic hepatitis C","GSM3359787","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359787/suppl/GSM3359787_SH74L49_Cell2_20170627_2020_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359788","SL-165 chronic hepatitis C","GSM3359788","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359788/suppl/GSM3359788_SH74L49_Cell3_20170627_2021_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359789","SL-168 chronic hepatitis C","GSM3359789","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359789/suppl/GSM3359789_SH74L49_Cell4_20170627_2022_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359790","AD-7 chronic hepatitis C","GSM3359790","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359790/suppl/GSM3359790_SH68J30_Cell1_20161221_1547_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359791","AD-116 chronic hepatitis C","GSM3359791","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359791/suppl/GSM3359791_SH68J35_Cell2_20161221_1608_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359792","AD-1 chronic hepatitis C","GSM3359792","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359792/suppl/GSM3359792_SH68Y44_Cell1_20161222_1505_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359793","AD-26 chronic hepatitis C","GSM3359793","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359793/suppl/GSM3359793_SH68Y44_Cell2_20161222_1506_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359794","AD-59 chronic hepatitis C","GSM3359794","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359794/suppl/GSM3359794_SH68Y44_Cell3_20161222_1507_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359795","SL-35 chronic hepatitis C","GSM3359795","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359795/suppl/GSM3359795_SH68Y44_Cell4_20161222_1508_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359796","SL-44 chronic hepatitis C","GSM3359796","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359796/suppl/GSM3359796_SH68Y45_Cell1_20161222_1509_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359797","SL-173 chronic hepatitis C","GSM3359797","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359797/suppl/GSM3359797_SH68Y45_Cell2_20161222_1510_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359798","SL-192 chronic hepatitis C","GSM3359798","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359798/suppl/GSM3359798_SH68Y45_Cell3_20161222_1511_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359799","SL-293 chronic hepatitis C","GSM3359799","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359799/suppl/GSM3359799_SH68Y45_Cell4_20161222_1512_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359800","SR-3 chronic hepatitis C","GSM3359800","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359800/suppl/GSM3359800_SH68Y46_Cell1_20161222_1513_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359801","SR-16 chronic hepatitis C","GSM3359801","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359801/suppl/GSM3359801_SH68Y46_Cell2_20161222_1514_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359802","SL-48 chronic hepatitis C","GSM3359802","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359802/suppl/GSM3359802_SH74L44_Cell2_20170627_2012_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359803","SL-153 chronic hepatitis C","GSM3359803","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359803/suppl/GSM3359803_SH74L45_Cell1_20170627_2015_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359804","SL-341 chronic hepatitis C","GSM3359804","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359804/suppl/GSM3359804_SH74L50_Cell1_20170627_2023_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359805","AD-10 chronic hepatitis C","GSM3359805","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359805/suppl/GSM3359805_SH68Y46_Cell3_20161222_1515_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359806","AD-40 chronic hepatitis C","GSM3359806","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359806/suppl/GSM3359806_SH68Y46_Cell4_20161222_1516_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359807","AD-44 chronic hepatitis C","GSM3359807","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359807/suppl/GSM3359807_SH68Y47_Cell1_20161222_1517_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359808","AD-45 chronic hepatitis C","GSM3359808","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359808/suppl/GSM3359808_SH68Y47_Cell2_20161222_1518_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359809","AD-49 chronic hepatitis C","GSM3359809","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359809/suppl/GSM3359809_SH68Y47_Cell3_20161222_1519_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359810","AD-50 chronic hepatitis C","GSM3359810","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359810/suppl/GSM3359810_SH68Y47_Cell4_20161222_1520_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359811","AD-53 chronic hepatitis C","GSM3359811","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359811/suppl/GSM3359811_SH68Y48_Cell1_20161222_1521_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359812","AD-67 chronic hepatitis C","GSM3359812","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359812/suppl/GSM3359812_SH68Y48_Cell3_20161222_1523_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359813","AD-92 chronic hepatitis C","GSM3359813","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359813/suppl/GSM3359813_SH68Y48_Cell4_20161222_1524_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359814","AD-109 chronic hepatitis C","GSM3359814","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359814/suppl/GSM3359814_SH68Y49_Cell1_20161222_1525_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359815","AD-111 chronic hepatitis C","GSM3359815","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359815/suppl/GSM3359815_SH68Y49_Cell2_20161222_1526_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359816","AD-117 chronic hepatitis C","GSM3359816","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359816/suppl/GSM3359816_SH68Y49_Cell3_20161222_1527_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359817","AD-120 chronic hepatitis C","GSM3359817","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359817/suppl/GSM3359817_SH68Y49_Cell4_20161222_1528_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359818","AD-136 chronic hepatitis C","GSM3359818","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359818/suppl/GSM3359818_SH68Y50_Cell1_20161222_1529_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359819","AD-150 chronic hepatitis C","GSM3359819","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359819/suppl/GSM3359819_SH68Y50_Cell2_20161222_1530_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359820","SL-2 chronic hepatitis C","GSM3359820","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359820/suppl/GSM3359820_SH68Y50_Cell4_20161222_1532_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359821","SL-52 chronic hepatitis C","GSM3359821","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359821/suppl/GSM3359821_SH68Y51_Cell4_20161222_1536_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359822","SL-92 chronic hepatitis C","GSM3359822","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359822/suppl/GSM3359822_SH68Y52_Cell4_20161222_1540_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359823","SL-294 chronic hepatitis C","GSM3359823","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359823/suppl/GSM3359823_SH68Y57_Cell3_20161222_1559_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359824","SL-40 chronic hepatitis C","GSM3359824","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359824/suppl/GSM3359824_SH68Y51_Cell3_20161222_1535_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359825","SL-6 chronic hepatitis C","GSM3359825","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359825/suppl/GSM3359825_SH68Y51_Cell1_20161222_1533_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359826","SL-82 chronic hepatitis C","GSM3359826","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359826/suppl/GSM3359826_SH68Y52_Cell1_20161222_1537_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359827","SL-87 chronic hepatitis C","GSM3359827","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359827/suppl/GSM3359827_SH68Y52_Cell2_20161222_1538_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359828","SL-90 chronic hepatitis C","GSM3359828","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359828/suppl/GSM3359828_SH68Y52_Cell3_20161222_1539_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359829","SL-101 chronic hepatitis C","GSM3359829","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359829/suppl/GSM3359829_SH68Y53_Cell1_20161222_1541_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359830","SL-106 chronic hepatitis C","GSM3359830","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359830/suppl/GSM3359830_SH68Y53_Cell2_20161222_1542_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359831","SL-117 chronic hepatitis C","GSM3359831","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359831/suppl/GSM3359831_SH68Y53_Cell3_20161222_1543_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359832","SL-132 chronic hepatitis C","GSM3359832","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359832/suppl/GSM3359832_SH68Y53_Cell4_20161222_1544_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359833","SL-152 chronic hepatitis C","GSM3359833","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359833/suppl/GSM3359833_SH68Y54_Cell1_20161222_1545_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359834","SL-161 chronic hepatitis C","GSM3359834","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359834/suppl/GSM3359834_SH68Y54_Cell3_20161222_1547_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359835","SL-198 chronic hepatitis C","GSM3359835","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359835/suppl/GSM3359835_SH68Y55_Cell1_20161222_1549_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359836","SL-20 chronic hepatitis C","GSM3359836","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359836/suppl/GSM3359836_SH68Y51_Cell2_20161222_1534_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359837","SL-205 chronic hepatitis C","GSM3359837","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359837/suppl/GSM3359837_SH68Y55_Cell2_20161222_1550_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359838","SL-224 chronic hepatitis C","GSM3359838","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359838/suppl/GSM3359838_SH68Y55_Cell3_20161222_1551_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359839","SL-228 chronic hepatitis C","GSM3359839","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359839/suppl/GSM3359839_SH68Y55_Cell4_20161222_1552_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359840","SL-234 chronic hepatitis C","GSM3359840","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359840/suppl/GSM3359840_SH68Y56_Cell1_20161222_1553_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359841","SL-257 chronic hepatitis C","GSM3359841","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359841/suppl/GSM3359841_SH68Y56_Cell4_20161222_1556_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359842","SL-263 chronic hepatitis C","GSM3359842","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359842/suppl/GSM3359842_SH68Y57_Cell1_20161222_1557_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359843","SL-272 chronic hepatitis C","GSM3359843","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359843/suppl/GSM3359843_SH68Y57_Cell2_20161222_1558_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359844","SR-88 chronic hepatitis C","GSM3359844","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359844/suppl/GSM3359844_SH68Y58_Cell1_20161222_1601_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359845","SR-53 chronic hepatitis C","GSM3359845","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359845/suppl/GSM3359845_SH68Y62_Cell2_20161227_1142_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359846","SL-301 chronic hepatitis C","GSM3359846","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359846/suppl/GSM3359846_SH74L50_Cell2_20170627_2024_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359847","SR-168 chronic hepatitis C","GSM3359847","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359847/suppl/GSM3359847_SH74L50_Cell3_20170627_2025_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359848","SL-323 chronic hepatitis C","GSM3359848","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359848/suppl/GSM3359848_SH74L50_Cell4_20170627_2026_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359849","AD-54 chronic hepatitis C","GSM3359849","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359849/suppl/GSM3359849_SH68Y48_Cell2_20161222_1522_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359850","AD-151 chronic hepatitis C","GSM3359850","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359850/suppl/GSM3359850_SH68Y50_Cell3_20161222_1531_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359851","SL-158 chronic hepatitis C","GSM3359851","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359851/suppl/GSM3359851_SH68Y54_Cell2_20161222_1546_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359852","SL-167 chronic hepatitis C","GSM3359852","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359852/suppl/GSM3359852_SH68Y54_Cell4_20161222_1548_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359853","SL-248 chronic hepatitis C","GSM3359853","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359853/suppl/GSM3359853_SH68Y56_Cell2_20161222_1554_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359854","SL-252 chronic hepatitis C","GSM3359854","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359854/suppl/GSM3359854_SH68Y56_Cell3_20161222_1555_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359855","SR-6 chronic hepatitis C","GSM3359855","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359855/suppl/GSM3359855_SH68Y57_Cell4_20161222_1600_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359856","SR-158 chronic hepatitis C","GSM3359856","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359856/suppl/GSM3359856_SH68Y58_Cell2_20161222_1602_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359857","AD-22 chronic hepatitis C","GSM3359857","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359857/suppl/GSM3359857_SH68Y58_Cell3_20161222_1603_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359858","AD-24 chronic hepatitis C","GSM3359858","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359858/suppl/GSM3359858_SH68Y58_Cell4_20161222_1604_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359859","AD-47 chronic hepatitis C","GSM3359859","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359859/suppl/GSM3359859_SH68Y59_Cell1_20161222_1605_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359860","AD-57 chronic hepatitis C","GSM3359860","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359860/suppl/GSM3359860_SH68Y59_Cell2_20161222_1606_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359861","AD-75 chronic hepatitis C","GSM3359861","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359861/suppl/GSM3359861_SH68Y59_Cell3_20161222_1607_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359862","AD-106 chronic hepatitis C","GSM3359862","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359862/suppl/GSM3359862_SH68Y59_Cell4_20161222_1608_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359863","AD-138 chronic hepatitis C","GSM3359863","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359863/suppl/GSM3359863_SH68Y60_Cell1_20161222_1609_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359864","AD-148 chronic hepatitis C","GSM3359864","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359864/suppl/GSM3359864_SH68Y60_Cell2_20161222_1610_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359865","SL-15 chronic hepatitis C","GSM3359865","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359865/suppl/GSM3359865_SH68Y60_Cell3_20161222_1611_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359866","SL-46 chronic hepatitis C","GSM3359866","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359866/suppl/GSM3359866_SH68Y60_Cell4_20161222_1612_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359867","SL-121 chronic hepatitis C","GSM3359867","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359867/suppl/GSM3359867_SH68Y61_Cell1_20161222_1613_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359868","SL-137 chronic hepatitis C","GSM3359868","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359868/suppl/GSM3359868_SH68Y61_Cell2_20161222_1614_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359869","SL-151 chronic hepatitis C","GSM3359869","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359869/suppl/GSM3359869_SH68Y61_Cell3_20161222_1615_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359870","SR-14 chronic hepatitis C","GSM3359870","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359870/suppl/GSM3359870_SH68Y61_Cell4_20161222_1616_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359871","SR-23 chronic hepatitis C","GSM3359871","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359871/suppl/GSM3359871_SH68Y62_Cell1_20161227_1141_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359872","SR-80 chronic hepatitis C","GSM3359872","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359872/suppl/GSM3359872_SH68Y62_Cell3_20161227_1143_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
"GSM3359873","SR-103 chronic hepatitis C","GSM3359873","Public on Jan 24 2020","Aug 28 2018","Jan 24 2020","RNA","1","exosome","Homo sapiens","disease state: chronic hepatitis C","Sample was obtained after treatment of direct anti-viral drug.","Exosome in serum from chronic hepatitis C patients was concentrated by Exoquick.","total RNA","Total RNA from liver biopsy was extracted commercially available kit (miReasy mini kit (Qiagen)).","Cy5","Extracted total RNA was labeled with Cy5 using the 3D-Gene miRNA labeling kit (Toray Industries Inc., Tokyo, Japan).","9606","Hybridized for 16 h at 32 C with rotary shake (250 rpm). Hybridization buffer and washing protocol was followed by the protocol supplied by TORAY Industries, Inc..","3D-Gene Scanner ((Toray Industries Inc., Tokyo, Japan) was used for scanning. Images were quantified using Extraction(Toray Industries Inc., Tokyo, Japan).","The raw data of each spot was normalized by substitution with a mean intensity of the background signal determined by all blank spots’ signal intensities of 95% confidence intervals.","GPL21263","Satoko,,Takizawa","satoko_takizawa@nts.toray.co.jp","+81-467-32-9351","Toray Industries, Inc.","6-10-1, Tebiro","Kanagawa","Kamakura","2480036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3359nnn/GSM3359873/suppl/GSM3359873_SH68Y62_Cell4_20161227_1144_1Color_IntegratedResult.txt.gz","2565","chronic hepatitis C"
